SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Sage Therapeutics, Inc. (Nasdaq – SAGE)
BALA CYNWYD – June 17, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Sage Therapeutics, Inc. (“Sage Therapeutics” or the “Company”) (Nasdaq – SAGE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Supernus Pharmaceuticals, Inc. (Nasdaq – SUPN). Under the terms of the transaction, Supernus will commence a tender offer to acquire all of the outstanding shares of Sage for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total possible consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million).
The investigation concerns whether the Sage Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.
If you own shares of Sage Therapeutics stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.